Voyager Transaction
Summary
On April 23, 2025, VERAXA Biotech AG and Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ: VACH), announced that they have entered into a definitive business combination agreement.The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company focused on the development of a comprehensive pipeline of next-generation cancer therapies. Upon closing of the transaction, VERAXA Biotech AG is expected to list on NASDAQ under the proposed ticker symbol “VERX.”
On January 23, 2026, VERAXA Biotech AG published the invitation to its Extraordinary General Meeting, which will take place on Friday, February 27, 2026, at 2 PM Central European Time at the Zunfthaus zur Saffran, Limmatquai 54, 8001 Zurich. More infotmation is being provided under "Events & conferences".
VERAXA Biotech AG
Dr. Christoph Antz
Chief Executive Officer
antz@veraxa.com
Voyager Acquisition Corp.
Mr. Adeel Rouf
Chief Executive Officer, and Director
adeel@voyageracq.com
Valency Communications
For Media and Investors
Mario Brkulj
Valency Communications mbrkulj@valencycomms.eu
Press releases in connection with the Voyager transaction
